Nothing Special   »   [go: up one dir, main page]

HK1210035A1 - Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same - Google Patents

Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same

Info

Publication number
HK1210035A1
HK1210035A1 HK15110855.6A HK15110855A HK1210035A1 HK 1210035 A1 HK1210035 A1 HK 1210035A1 HK 15110855 A HK15110855 A HK 15110855A HK 1210035 A1 HK1210035 A1 HK 1210035A1
Authority
HK
Hong Kong
Prior art keywords
aqueous dispersion
encapsulating liposome
liposome aqueous
stable oxaliplatin
stabilizing same
Prior art date
Application number
HK15110855.6A
Other languages
English (en)
Chinese (zh)
Inventor
祐輔 土井
竜弘 石田
Original Assignee
Taiho Pharmaceutical Co Ltd
Univ Tokushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, Univ Tokushima filed Critical Taiho Pharmaceutical Co Ltd
Publication of HK1210035A1 publication Critical patent/HK1210035A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15110855.6A 2012-08-10 2015-11-03 Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same HK1210035A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012178971 2012-08-10
PCT/JP2013/071720 WO2014025042A1 (ja) 2012-08-10 2013-08-09 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法

Publications (1)

Publication Number Publication Date
HK1210035A1 true HK1210035A1 (en) 2016-04-15

Family

ID=50068258

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110855.6A HK1210035A1 (en) 2012-08-10 2015-11-03 Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same

Country Status (8)

Country Link
US (2) US10383822B2 (xx)
EP (1) EP2883542B1 (xx)
JP (1) JP6230538B2 (xx)
CN (1) CN104703594B (xx)
ES (1) ES2733061T3 (xx)
HK (1) HK1210035A1 (xx)
SG (2) SG11201501010QA (xx)
WO (1) WO2014025042A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968144A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposome oxaliplatin compositions for cancer therapy
CA2998968C (en) 2015-09-18 2024-03-19 Technische Universitat Munchen Ligands for integrin .alpha.v.beta.6, synthesis and uses thereof
WO2018043530A1 (ja) 2016-08-31 2018-03-08 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2018167295A1 (en) 2017-03-17 2018-09-20 Technische Universität München LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
TW202002989A (zh) * 2018-03-13 2020-01-16 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用試劑盒

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2184834A1 (en) * 1994-03-11 1995-09-14 Yoshiyuki Mori Liposome preparation
JP3547755B2 (ja) 1994-08-08 2004-07-28 デビオファーム・エス・アー オキサリプラティヌムの医薬的に安定な製剤
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
AU2230497A (en) 1996-02-26 1997-09-10 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
ATE381932T1 (de) 1996-06-18 2008-01-15 Kyowa Hakko Kogyo Kk Liposomale zubereitungen von indolocarbazol- derivaten
JP4368513B2 (ja) 1999-12-27 2009-11-18 富士フイルム株式会社 画像処理方法および装置並びに記録媒体
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040002284A1 (en) * 2002-06-27 2004-01-01 Leal Jose E. Illuminated throwing toy
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
AU2005240131C1 (en) * 2004-05-03 2014-05-08 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8078919B2 (en) * 2005-06-14 2011-12-13 Hitachi Global Storage Technologies Netherlands B.V. Method, apparatus and program storage device for managing multiple step processes triggered by a signal
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2008030818A2 (en) * 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery

Also Published As

Publication number Publication date
US10993913B2 (en) 2021-05-04
EP2883542A1 (en) 2015-06-17
EP2883542B1 (en) 2019-05-01
US10383822B2 (en) 2019-08-20
JPWO2014025042A1 (ja) 2016-07-25
SG11201501010QA (en) 2015-04-29
US20190321294A1 (en) 2019-10-24
EP2883542A4 (en) 2016-01-06
WO2014025042A1 (ja) 2014-02-13
ES2733061T3 (es) 2019-11-27
CN104703594A (zh) 2015-06-10
CN104703594B (zh) 2018-01-23
US20150216801A1 (en) 2015-08-06
SG10201701063WA (en) 2017-04-27
JP6230538B2 (ja) 2017-11-15

Similar Documents

Publication Publication Date Title
HK1254894A1 (zh) 自動駕駛儀及其方法
IL238250A0 (en) Selective antisense compounds and their use
ZA201409071B (en) Controlled environment and method
HK1213131A1 (zh) 用於間斷接收的方法和裝置
GB2500915B (en) Arrangement and method
EP2898720A4 (en) SYSTEMS AND METHODS FOR INTERFERENCE ORIENTATION IN WI-FI
EP2866390A4 (en) COMMUNICATION METHOD AND SYSTEM
EP2825142A4 (en) SYSTEMS AND METHOD FOR BALANCE TESTING
HK1200384A1 (en) Pressure-regulating vial adaptors and methods
HK1200339A1 (en) W/o/w emulsion having long-term stability and method for producing same w/o/w
EP2898728A4 (en) COMMUNICATION SYSTEM AND METHOD
EP2762538A4 (en) Aqueous dispersion and process for its preparation
HK1210035A1 (en) Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
EP2927807A4 (en) METHOD FOR ACTIVATING A TERMINAL AND TERMINAL
GB2509397B (en) Rigid-stem active method and system
EP2774602A4 (en) Aqueous dispersion and process for its preparation
GB201223260D0 (en) Methods and apparatuses for facilitating communications
EP3041901A4 (en) Aqueous polyurethane dispersion
EP2873709A4 (en) METHOD FOR PRODUCING A HEAT RADIATION DISPERSION, HEAT RADIATION DISPERSING AND HEAT RADIATION SCREENS OF THE BODY
HK1201575A1 (en) Aqueous assembly and control method
ZA201504003B (en) Stabilizing system
EP2868742A4 (en) ITEM AND METHOD OF FILTRATION
PT2812291T (pt) Dispersão aquosa
EP2894197A4 (en) AQUEOUS DISPERSION, AND ADDITIVE FOR FRACTURATION WORK
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220804